Key Publications

  1. Benham H*, Nel HJ*, Law SC*, Mehdi AM*, Street S, Ramnoruth N, Pahau H, Lee BT, Ng J, Brunck MEG, Hyde C, Trouw LA, Dudek NL, Purcell AW, O’Sullivan BJ, ConnollyJE, Paul S, Lê Cao KA and R Thomas. Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients. Science Transl Med 2015, 7:290ra87. Available from http://stm.sciencemag.org/content/7/290/290ra87.full 
  2. Koning F*, Thomas R*, Rossjohn J* and R Toes*. From celiac disease to rheumatoid arthritis: common mechanisms, different antigens. Nat Rev Rheum 2015 doi: 10.1038/nrrheum.2015.59.
  3. Scally SW, Petersen J, Law SC, Dudek N, Nel HJ, Loh KL, Wijeyewickrema LC, Eckle S, Pike RN, McCluskey J, Toes RE, La Gruta NL, Purcell AW*, Reid HH*, Thomas R* and J Rossjohn*. A molecular basis for the association of the HLA-DRB1 locus, citrullination and rheumatoid arthritis. J Exp Med 2013, 210:2569-82.
  4. Thomas R. Dendritic cells and the promise of antigen-specific therapy in rheumatoid arthritis. Arthritis Res Ther 2013, 15:204.
  5. Law SC, Street S, Yu CHA, Capini C, Ramnoruth S, Nel HJ, Van Gorp E, Hyde C, Lau K, Purcell AW and R Thomas. T cell autoreactivity to citrullinated autoantigenic peptides in rheumatoid arthritis patients carrying HLA-DRB1 shared epitope alleles. Arthritis Res Ther 2012, 14:R118.
  6. Irvine K, Gallego P, An X, Denny J, Baskerville T, Flynn S, Thomas G, Wells C, Harris M, Cotterill A and R Thomas. Peripheral blood monocyte gene expression profile clinically stratifies patients with recent onset Type 1 Diabetes. Diabetes 2012, 61:1281-1290.
  7. Shklovskaya E, O’Sullivan BJ, Ng LG, Roediger B, Thomas R, Weninger W and B Fazekas de St Groth. Langerhans cells are pre-committed to immune tolerance induction. Proc Natl Acad USA 2011;108:18049-18054.
  8. O’Sullivan BJ*, Pai S*, Street S, An X, MacDonald KP, Wong M, Strutton G, Gerondakis S, Steptoe, RJ, Hill GR and R Thomas. Immunotherapy with costimulatory dendritic cells to control autoimmune inflammation. J Immunol 2011;187:4018-30.
  9. Yekollu SK, Thomas R and BJ O'Sullivan. Targeting curcusomes to inflammatory dendritic cells inhibits NF-kB and improves insulin resistance in obese mice. Diabetes 2011; 60:2928-38.
  10. Bertin-Maghit S, Pang D, O’Sullivan BJ , Best S, Duggan E, Paul S, Thomas HE, Kay TWH, Harrison LC, Steptoe R* and R Thomas*. IL-1ß produced in response to islet autoantigen presentation differentiates T-helper 17 cells at the expense of regulatory T cells: implications for the timing of tolerizing immunotherapy. Diabetes 2011; 60:248-57.
  11. Capini C, Jaturanpinyo M, Chang HI, Mutalik S, Street S, O’Sullivan BJ, Davies NM and R Thomas. Antigen-specific suppression of inflammatory arthritis using liposomes. J Immunol 2009 182:3556-65.
  12. Thompson Martin E*, Capini C*, Duggan E, Lutzky VP, Stumbles P, Pettit AR, O' Sullivan BJ and R Thomas. Antigen-specific suppression of established arthritis by dendritic cells deficient in NF-kappa B. Arthritis Rheum 2007, 56:2255-2266.
  13. Thompson AG, O'Sullivan BJ, Beamish H and R Thomas. T cells signaled by NF-K-B- dendritic cells are sensitized not anergic to subsequent activation. J Immunol 2004. 173:1671-80.
  14. Martin E, O'Sullivan BJ, Low P and R Thomas. Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interluekin-10. Immunity 2003. 18:155-67.
  15. O'Sullivan BJ and R Thomas. CD40 ligation conditions dendritic cells antigen presenting function through sustained activation of NFkB. J Immunol 2002. 168:5491-5498.